Phaseline

Companies › Santen SAS

Santen SAS: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Infectious disease, Ophthalmology, Respiratory.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Oxymetazoline (STN1013800)
Adrenergic receptor alpha agonist
ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1BPhase 3Acquired Blepharophimosis; Sleep Apnea; Perioperative Respiratory Adverse Events; Nasal Obstruction–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02630121Oxymetazoline (STN1013800)Phase 4Sleep ApneaRespiratoryApr 2026
NCT06514612Oxymetazoline (STN1013800)Phase 3Acquired BlepharophimosisOphthalmologyAug 2026
NCT06830109Oxymetazoline (STN1013800)Phase 2Nasal ObstructionRespiratoryDec 2026
NCT07000877Oxymetazoline (STN1013800)Phase 4Perioperative Respiratory Adverse EventsInfectious diseaseMay 2028

Targets

ADRA1A (1) ADRA2A (1) ADRA2C (1) ADRA1D (1) ADRA1B (1)

Companies with the same targets

Opus Genetics Berlin-Chemie AG Menarini Group ARS Pharmaceuticals Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Tarian Pharma Alcon Research Acer Therapeutics Applied Biology

Companies built like this

Guangzhou Novaken Pharm Alimera Sciences Alcon Research VivaVision Biotech Materia Medica Holding

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.